<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of the management of patients with variceal bleeding</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of the management of patients with variceal bleeding</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of the management of patients with variceal bleeding</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arun J Sanyal, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Juan Carlos Garcia-Pagán, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce A Runyon, MD, FAASLD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 02, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Variceal bleeding is a gastrointestinal emergency that is one of the major causes of death in patients with cirrhosis. The outcome for patients with variceal bleeding depends on achieving hemostasis and avoiding complications related to bleeding or underlying chronic liver disease. </p><p>A rise in portal pressure (portal hypertension) occurs when there is resistance to outflow from the portal vein. Varices develop in order to decompress the hypertensive portal vein and return blood to the systemic circulation. The formation and progression of varices are discussed separately. (See  <a class="medical medical_review" href="/d/html/1244.html" rel="external">"Pathogenesis of variceal bleeding in patients with cirrhosis"</a>.)</p><p>Variceal bleeding is the most common cause of upper gastrointestinal bleeding in patients with cirrhosis and/or portal hypertension. However, patients with portal hypertension can also develop upper gastrointestinal bleeding from sources unrelated to portal hypertension (eg, peptic ulcer disease, Mallory-Weiss tear) [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/2644.html" rel="external">"Causes of upper gastrointestinal bleeding in adults"</a>.)</p><p>This topic presents an overview of the management of patients with variceal bleeding. Strategies for bleeding prevention are discussed separately: </p><p class="bulletIndent1"><span class="glyph">●</span>Preventing the first episode of variceal bleeding (see  <a class="medical medical_review" href="/d/html/1245.html" rel="external">"Primary prevention of bleeding from esophageal varices in patients with cirrhosis"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Preventing recurrent variceal bleeding (see  <a class="medical medical_review" href="/d/html/1252.html" rel="external">"Prevention of recurrent bleeding from esophageal varices in patients with cirrhosis"</a>)</p><p></p><p>The approach to and evaluation of adults with upper gastrointestinal bleeding from any source is presented separately. (See  <a class="medical medical_review" href="/d/html/2548.html" rel="external">"Approach to acute upper gastrointestinal bleeding in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>The existing literature is confounded by the variable use of terminology across studies. As a result, several definitions were agreed upon during a consensus conference, and this simplifies the evaluation of published studies and renders newer studies more comparable [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Time zero</strong> – The time of admission to a medical care facility.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinically significant bleeding </strong>– Defined by a transfusion requirement of two units of blood or more within 24 hours of time zero together with a systolic blood pressure below 100 mmHg, a postural systolic change &gt;20 mmHg, and/or a pulse rate &gt;100 beats per minute at time zero.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute variceal bleeding</strong> – The episode of acute bleeding is comprised of the time interval from hospital admission (time zero) to 120 hours (day 5).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment failure </strong>– Failure of therapy is defined by any of the following criteria if they occur within 120 hours of time zero:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fresh hematemesis or &gt;100 mL of fresh blood in the nasogastric aspirate &gt;2 hours after the start of a specific drug or endoscopic treatment</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Development of hypovolemic shock</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Drop in hemoglobin of ≥3 g/dL (30 g/L) within a 24-hour period</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Variceal rebleeding </strong>–<strong> </strong>Variceal rebleeding describes clinically significant bleeding that occurs ≥120 hours after the first hemorrhage, provided that hemostasis was initially achieved [<a href="#rid3">3</a>].</p><p></p><p class="headingAnchor" id="H2618160698"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Factors linked to the risk of variceal bleeding include size of varices, appearance of varices (eg, red wale marks or areas of thinning of the variceal wall), and the severity of liver disease. Predictive factors for variceal bleeding are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/1244.html" rel="external">"Pathogenesis of variceal bleeding in patients with cirrhosis", section on 'Predictive factors'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">PRINCIPLES OF ACUTE MANAGEMENT</span></p><p class="headingAnchor" id="H568623379"><span class="h2">Goals of therapy</span><span class="headingEndMark"> — </span>Treatment goals during an episode of acute bleeding are to: </p><p class="bulletIndent1"><span class="glyph">●</span>Restore and maintain hemodynamic stability</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Restore and maintain adequate oxygenation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Control bleeding</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prevent complications </p><p></p><p>Management of acute variceal bleeding often requires multidisciplinary care (hepatology, critical care, interventional radiology).</p><p class="headingAnchor" id="H448972725"><span class="h2">Initial measures</span></p><p class="headingAnchor" id="H5"><span class="h3">Resuscitation and support</span><span class="headingEndMark"> — </span>General resuscitative and supportive measures for patients with gastrointestinal bleeding who have a history of or are at risk for varices (eg, patients with jaundice or cirrhosis) include [<a href="#rid4">4</a>]  (<a class="graphic graphic_table graphicRef72195" href="/d/graphic/72195.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous access and fluids</strong> – After intravenous access (eg, two 16 gauge peripheral intravenous catheters or a central venous catheter) is established, fluid resuscitation should begin immediately. The approach to fluid resuscitation in patients who are hemodynamically unstable is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/98976.html" rel="external">"Evaluation of and initial approach to the adult patient with undifferentiated hypotension and shock", section on 'Hemodynamic support'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supplemental oxygenation and airway protection</strong> – Supplemental oxygen is initially provided by nasal cannula; however, endotracheal intubation to protect the patient's airway is usually performed for patients with hemodynamic instability, altered mental status, and/or ongoing hematemesis [<a href="#rid5">5</a>]. Extubation should be performed when possible after endoscopy because endotracheal intubation may be a risk factor for respiratory infection [<a href="#rid6">6</a>]. Extubation management is discussed separately. (See  <a class="medical medical_review" href="/d/html/1634.html" rel="external">"Extubation management in the adult intensive care unit"</a>.)  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional measures</strong> – For patients with ongoing hematemesis, initial care also includes: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nasogastric tube – Nasogastric tube placement may help to remove particulate matter, fresh blood, and clots from the stomach prior to endoscopy. However, we perform nasogastric tube placement cautiously because of the risk of pulmonary infection [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/15070.html" rel="external">"Inpatient placement and management of nasogastric and nasoenteric tubes in adults", section on 'Tube placement'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">Erythromycin</a> – For patients without contraindications (eg, QTc prolongation), erythromycin may be given prior to upper endoscopy to improve endoscopic visualization [<a href="#rid7">7,8</a>]. The use of prokinetic agents including dosing and administration is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/2548.html" rel="external">"Approach to acute upper gastrointestinal bleeding in adults", section on 'Prokinetics'</a>.) </p><p></p><p class="headingAnchor" id="H1333342822"><span class="h3">Blood products</span><span class="headingEndMark"> — </span>Patients with active bleeding and hypovolemia often require blood products. However, patients with cirrhosis have a form of rebalanced hemostasis, and conventional measures of clotting (eg, prothrombin time) are not particularly reflective of bleeding risk. These issues are presented separately. (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease"</a>.)</p><p>Measures to improve hemostasis include: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Red blood cells</strong> – We initiate blood transfusion if hemoglobin is &lt;7 g/dL (70 g/L) for most patients, with a goal of maintaining the hemoglobin at a level between ≥7 g/dL (70 g/L) and &lt;9 g/dL (90 g/L). However, for patients at increased risk of adverse events in the setting of anemia (ie, those with unstable coronary artery disease or ongoing active bleeding), our goal is to maintain the hemoglobin at a level of ≥9 g/dL (90 g/L). The patient's intravascular volume status is monitored to avoid volume overload because of the risk of rebound portal hypertension and induction of rebleeding [<a href="#rid9">9-11</a>]. (See  <a class="medical medical_review" href="/d/html/14942.html" rel="external">"Intraoperative fluid management", section on 'Monitoring intravascular volume status'</a>.)</p><p></p><p class="bulletIndent1">Patients who receive more than five to six units of red blood cells may be transfused with plasma and platelets to compensate for losses. Protocols for and complications of massive transfusion are discussed separately. (See  <a class="medical medical_review" href="/d/html/7931.html" rel="external">"Massive blood transfusion"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other blood products</strong> – For patients with variceal bleeding and coagulopathy, correcting the coagulopathy may be indicated for selected patients (eg, those in whom endoscopic therapy does not control bleeding). However, laboratory tests such as prothrombin time/international normalized ratio (PT/INR) and activated partial thromboplastin time, do not accurately reflect the hemostatic status of patients with decompensated cirrhosis. We do not routinely use fresh frozen plasma because it does not correct coagulopathy and may lead to volume overload and worsening of portal hypertension. In addition, we do not routinely use platelet transfusion or fibrinogen supplementation because platelet count and fibrinogen levels have not been associated with the risk of rebleeding or of failing to achieve endoscopic hemostasis [<a href="#rid6">6</a>]. Hemostatic products for patients with active gastrointestinal bleeding in the setting of liver disease is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'Bleeding'</a> and  <a class="medical medical_review" href="/d/html/7943.html" rel="external">"Cryoprecipitate and fibrinogen concentrate"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">Vitamin K</a> – Patients at risk of vitamin K deficiency (eg, those with cholestatic liver disease) can be treated with vitamin K. (See  <a class="medical medical_review" href="/d/html/2624.html" rel="external">"Overview of vitamin K", section on 'Vitamin K deficiency'</a>.) </p><p></p><p class="headingAnchor" id="H1115032804"><span class="h3">Antibiotic prophylaxis</span><span class="headingEndMark"> — </span>Patients with cirrhosis who present with upper gastrointestinal bleeding are given prophylactic antibiotics, preferably before endoscopy (although effectiveness has also been demonstrated when given after endoscopy) [<a href="#rid12">12-14</a>]. We typically use a broad spectrum antibiotic such as <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> (1 g intravenously daily for seven days). For patients who are discharged before seven days of intravenous antibiotic therapy, we transition to an oral antibiotic, such as <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> (500 mg every 12 hours), to complete a total of seven days of antibiotic therapy. (See  <a class="medical medical_review" href="/d/html/1248.html" rel="external">"Spontaneous bacterial peritonitis in adults: Treatment and prophylaxis", section on 'Choosing a regimen'</a>.)</p><p>For patients with cirrhosis and gastrointestinal (GI) bleeding, prophylactic antibiotics reduce the risk of mortality, infections (eg, spontaneous bacterial peritonitis, urinary tract infections), and rebleeding. In a meta-analysis of 12 trials including over 1200 patients with cirrhosis and GI bleeding, antibiotic prophylaxis was compared with either placebo or no intervention, and the benefit of antibiotic use was demonstrated with regard to mortality (relative risk [RR] 0.79, 95% CI 0.63-0.98), bacterial infections (RR 0.35, 95% CI 0.26-0.47), and rebleeding (RR 0.53, 95% CI 0.38-0.74) [<a href="#rid13">13</a>]. </p><p>Preliminary data suggested that selected patients (eg, those with Child-Pugh class A cirrhosis) may be at lower risk for bacterial infection and may not need antibiotic prophylaxis [<a href="#rid15">15</a>]. However, additional studies are needed to confirm these findings.</p><p>We typically use <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> because most infections are due to gram-negative bacteria and because ceftriaxone was superior to <a class="drug drug_general" data-topicid="9710" href="/d/drug information/9710.html" rel="external">norfloxacin</a> for preventing infection in patients with cirrhosis in a randomized trial [<a href="#rid16">16,17</a>]. Important factors in the choice of antibiotics include individual patient characteristics (eg, prior history of antibiotic exposure or infection) and local patterns of antibiotic resistance. Quinolone resistance, for example, has become an increasing problem in patients with cirrhosis in some centers [<a href="#rid18">18</a>]. The possibility of quinolone resistance is a particular concern in patients who have been receiving prophylactic norfloxacin for the prevention of spontaneous bacterial peritonitis. In a trial including 111 patients with cirrhosis and GI bleeding, patients receiving oral norfloxacin had higher rates of developing infections (26 versus 11 percent) or spontaneous bacterial peritonitis (12 versus 2 percent) compared with patients given intravenous ceftriaxone [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/1248.html" rel="external">"Spontaneous bacterial peritonitis in adults: Treatment and prophylaxis", section on 'Antibiotic resistance'</a>.)</p><p class="headingAnchor" id="H4061954640"><span class="h3">Pharmacologic therapy for bleeding</span><span class="headingEndMark"> — </span>Pharmacologic therapy for patients with variceal bleeding (eg, <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a>, <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a>) is discussed separately. (See  <a class="medical medical_review" href="/d/html/1260.html" rel="external">"Methods to achieve hemostasis in patients with acute variceal hemorrhage"</a>.)</p><p class="headingAnchor" id="H3984783952"><span class="h3">Medication adjustments</span><span class="headingEndMark"> — </span>The decision of whether to continue outpatient medications in patients with cirrhosis and variceal bleeding depends on multiple factors, including the specific medication (eg, antihypertensive agent), the severity of bleeding, hemodynamic status of the patient, the functional status of other organs (ie, kidney, brain), and the presence and severity of underlying cardiovascular disease. Given the multiple variables, medical decision-making is individualized in consultation with the critical care team. </p><p>For example, we stop antihypertensive medications (eg, beta blockers) for patients with active variceal bleeding and hemodynamic instability, and we monitor them for signs that such medication may be restarted (ie, cessation of bleeding and hemodynamic stability).</p><p>For patients with variceal bleeding, we typically discontinue proton pump inhibitors that were initiated prior to endoscopy after the source of bleeding is confirmed endoscopically. Prolonged use of a proton pump inhibitor (ie, &gt;28 days) has been associated with increased risk for hepatic encephalopathy and for further decompensation [<a href="#rid19">19,20</a>].</p><p class="headingAnchor" id="H1217863665"><span class="h3">Electrolyte and vitamin repletion</span><span class="headingEndMark"> — </span>We monitor electrolytes (eg, phosphorus, potassium, magnesium) for all patients with variceal bleeding, and we give <a class="drug drug_general" data-topicid="9988" href="/d/drug information/9988.html" rel="external">thiamine</a> to patients with alcohol use disorder. Thiamine is given prior to or along with glucose intravenous infusion to prevent precipitating Wernicke encephalopathy. The management of patients with alcohol use disorder is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/14614.html" rel="external">"Nutritional status in patients with sustained heavy alcohol use", section on 'Supplementation'</a> and  <a class="medical medical_review" href="/d/html/323.html" rel="external">"Management of moderate and severe alcohol withdrawal syndromes"</a> and  <a class="medical medical_review" href="/d/html/4818.html" rel="external">"Wernicke encephalopathy"</a>.) </p><p>Patients with cirrhosis may have nutritional deficiencies and thus are prone to electrolyte abnormalities. In particular, hypophosphatemia and hypokalemia may develop during the hospitalization, especially after dextrose infusions, which raise serum insulin concentrations; insulin drives both phosphate and potassium into the cells [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/835.html" rel="external">"Hypophosphatemia: Evaluation and treatment", section on 'Patients with alcohol use disorder'</a>.)</p><p class="headingAnchor" id="H2630966276"><span class="h2">Urgent endoscopy</span><span class="headingEndMark"> — </span>Upper endoscopy should be performed after fluid resuscitation and within 12 hours of hospital admission [<a href="#rid22">22,23</a>], and endoscopic therapy to control active bleeding is discussed separately. (See  <a class="medical medical_review" href="/d/html/1260.html" rel="external">"Methods to achieve hemostasis in patients with acute variceal hemorrhage"</a>.)</p><p class="headingAnchor" id="H1383832178"><span class="h2">Subsequent measures</span></p><p class="headingAnchor" id="H1366869346"><span class="h3">Nutritional support</span><span class="headingEndMark"> — </span>For hemodynamically stable patients, we typically wait a minimum of 48 to 72 hours after an episode of acute variceal bleeding prior to resuming enteral nutrition either orally or via nasogastric tube. Enteral nutrition increases splanchnic blood flow, which may lead to an increase in portal pressure and the risk of rebleeding [<a href="#rid24">24,25</a>]. The goals and delivery of enteral nutrition for critically ill patients is discussed separately. (See  <a class="medical medical_review" href="/d/html/1617.html" rel="external">"Nutrition support in intubated critically ill adult patients: Initial evaluation and prescription"</a> and  <a class="medical medical_review" href="/d/html/1605.html" rel="external">"Nutrition support in intubated critically ill adult patients: Enteral nutrition"</a>.)</p><p class="headingAnchor" id="H2257014631"><span class="h3">Additional studies</span><span class="headingEndMark"> — </span>We typically obtain an abdominal ultrasound with Doppler imaging to exclude portal vein thrombosis after the patient has been resuscitated and endoscopy has been performed. (See <a class="local">'Initial measures'</a> above and <a class="local">'Urgent endoscopy'</a> above and  <a class="medical medical_review" href="/d/html/3579.html" rel="external">"Acute portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management"</a>.)</p><p>If initial pharmacologic and endoscopic therapy fails to stop variceal bleeding, a transjugular intrahepatic portosystemic shunt (TIPS) is a subsequent therapeutic option. The indications and contraindications to TIPS placement, in addition to the role of TIPS in treating patients with variceal bleeding, is discussed separately. (See  <a class="medical medical_review" href="/d/html/1265.html" rel="external">"Overview of transjugular intrahepatic portosystemic shunts (TIPS)"</a>.)</p><p class="headingAnchor" id="H3229479457"><span class="h2">Complications</span><span class="headingEndMark"> — </span>Control of active variceal bleeding is usually achieved; however, some patients with cirrhosis develop complications during the hospital course. Major complications that can occur and may increase mortality risk include pneumonia, sepsis, acute-on-chronic liver failure, hepatic encephalopathy, and renal failure [<a href="#rid17">17,26</a>]. It is not unusual for multiple complications to develop simultaneously.</p><p class="headingAnchor" id="H11"><span class="h3">Hepatic encephalopathy</span><span class="headingEndMark"> — </span>Hepatic encephalopathy is managed with <a class="drug drug_general" data-topicid="9543" href="/d/drug information/9543.html" rel="external">lactulose</a> [<a href="#rid27">27</a>], with control of active bleeding, and with correction of other precipitating causes (eg, electrolyte abnormalities, infection). Management of hepatic encephalopathy is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/1255.html" rel="external">"Hepatic encephalopathy in adults: Treatment"</a> and  <a class="medical medical_review" href="/d/html/1237.html" rel="external">"Hepatic encephalopathy in adults: Clinical manifestations and diagnosis", section on 'Evaluation for precipitating causes'</a>.) </p><p>For example, hypokalemia can promote the development of hepatic encephalopathy via increased renal ammonia production. (See  <a class="medical medical_review" href="/d/html/1257.html" rel="external">"Hepatic encephalopathy: Pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/2295.html" rel="external">"Hypokalemia-induced kidney dysfunction"</a>.)</p><p class="headingAnchor" id="H263498108"><span class="h3">Renal failure</span><span class="headingEndMark"> — </span>The risk of renal failure (due either to acute tubular necrosis or to hepatorenal syndrome) can be minimized by adequate volume replacement and by avoiding nephrotoxic drugs (eg, aminoglycosides) and mismatched transfusions. Hepatorenal syndrome that occurs in the setting of gastrointestinal bleeding is discussed separately. (See  <a class="medical medical_review" href="/d/html/2308.html" rel="external">"Hepatorenal syndrome"</a>.)</p><p class="headingAnchor" id="H3988954326"><span class="h3">Other complications</span><span class="headingEndMark"> — </span>Complications related to the specific therapy used to control variceal bleeding (eg, pharmacologic therapy, endoscopic therapy, TIPS) are discussed separately. (See  <a class="medical medical_review" href="/d/html/1260.html" rel="external">"Methods to achieve hemostasis in patients with acute variceal hemorrhage"</a> and  <a class="medical medical_review" href="/d/html/1251.html" rel="external">"Transjugular intrahepatic portosystemic shunts: Postprocedure care and complications"</a>.) </p><p class="headingAnchor" id="H2423751591"><span class="h1">PREVENTING RECURRENT BLEEDING</span><span class="headingEndMark"> — </span>Patients who recover from acute variceal bleeding are at risk for rebleeding, and interventions to prevent recurrent bleeding are discussed separately. (See  <a class="medical medical_review" href="/d/html/1252.html" rel="external">"Prevention of recurrent bleeding from esophageal varices in patients with cirrhosis"</a>.)</p><p class="headingAnchor" id="H1609082014"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114134.html" rel="external">"Society guideline links: Gastrointestinal bleeding in adults"</a>.)</p><p class="headingAnchor" id="H2160949957"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/16190.html" rel="external">"Patient education: GI bleed (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/4581.html" rel="external">"Patient education: Esophageal varices (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background </strong>– Variceal bleeding is a gastrointestinal emergency that is one of the major causes of death in patients with cirrhosis. The outcome of an episode of variceal bleeding depends on achieving hemostasis and avoiding complications related to bleeding or underlying chronic liver disease. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1">Factors linked to the risk of variceal bleeding include size of varices, appearance of varices (eg, red wale marks or areas of thinning of the variceal wall), and the severity of liver disease. (See <a class="local">'Risk factors'</a> above and  <a class="medical medical_review" href="/d/html/1244.html" rel="external">"Pathogenesis of variceal bleeding in patients with cirrhosis", section on 'Predictive factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of therapy </strong>– For patients with acute variceal bleeding, goals of treatment are (see <a class="local">'Goals of therapy'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Restore and maintain hemodynamic stability</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Restore and maintain adequate oxygenation</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Control bleeding</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prevent complications </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial measures</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>General measures – For patients with cirrhosis and gastrointestinal bleeding, general initial measures include intravenous access, intravenous fluids, and supplemental oxygen, and airway protection. A table outlining the clinical features and emergency management of acute severe upper gastrointestinal bleeding in adults is provided  (<a class="graphic graphic_table graphicRef72195" href="/d/graphic/72195.html" rel="external">table 1</a>). (See <a class="local">'Resuscitation and support'</a> above and  <a class="medical medical_review" href="/d/html/2548.html" rel="external">"Approach to acute upper gastrointestinal bleeding in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antibiotic prophylaxis – For patients with cirrhosis who present with gastrointestinal bleeding, we recommend prophylactic antibiotic therapy rather than no antibiotics because antibiotic prophylaxis reduces the risk of mortality, infection, and rebleeding (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). We typically use a course of <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> (1 g intravenously daily for seven days). (See <a class="local">'Antibiotic prophylaxis'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pharmacologic therapy – The use of pharmacologic therapy to control variceal bleeding is discussed separately. (See  <a class="medical medical_review" href="/d/html/1260.html" rel="external">"Methods to achieve hemostasis in patients with acute variceal hemorrhage", section on 'Pharmacologic therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endoscopy</strong> – For patients with cirrhosis and gastrointestinal bleeding, upper endoscopy should be performed after fluid resuscitation and within 12 hours of hospital admission. Endoscopic therapy to control active bleeding is discussed separately. (See <a class="local">'Urgent endoscopy'</a> above and  <a class="medical medical_review" href="/d/html/1260.html" rel="external">"Methods to achieve hemostasis in patients with acute variceal hemorrhage"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse events</strong> – For most patients with variceal bleeding, hemostasis is achieved; however, patients with cirrhosis are at risk for complications during the hospital course. Major complications include pneumonia, sepsis, acute-on-chronic liver failure, hepatic encephalopathy, and renal failure. (See <a class="local">'Complications'</a> above and  <a class="medical medical_review" href="/d/html/3570.html" rel="external">"Acute liver failure in adults: Management and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preventing recurrent bleeding</strong> – Patients who recover from acute variceal bleeding are at risk for rebleeding, and interventions to prevent recurrent bleeding are discussed separately. (See  <a class="medical medical_review" href="/d/html/1252.html" rel="external">"Prevention of recurrent bleeding from esophageal varices in patients with cirrhosis"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lyles T, Elliott A, Rockey DC. A risk scoring system to predict in-hospital mortality in patients with cirrhosis presenting with upper gastrointestinal bleeding. J Clin Gastroenterol 2014; 48:712.</a></li><li><a class="nounderline abstract_t">de Franchis R, Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53:762.</a></li><li><a class="nounderline abstract_t">Tripathi D, Stanley AJ, Hayes PC, et al. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut 2015; 64:1680.</a></li><li><a class="nounderline abstract_t">Simonetto DA, Liu M, Kamath PS. Portal Hypertension and Related Complications: Diagnosis and Management. Mayo Clin Proc 2019; 94:714.</a></li><li><a class="nounderline abstract_t">Rudolph SJ, Landsverk BK, Freeman ML. Endotracheal intubation for airway protection during endoscopy for severe upper GI hemorrhage. Gastrointest Endosc 2003; 57:58.</a></li><li><a class="nounderline abstract_t">de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol 2022; 76:959.</a></li><li><a class="nounderline abstract_t">Pateron D, Vicaut E, Debuc E, et al. Erythromycin infusion or gastric lavage for upper gastrointestinal bleeding: a multicenter randomized controlled trial. Ann Emerg Med 2011; 57:582.</a></li><li><a class="nounderline abstract_t">Altraif I, Handoo FA, Aljumah A, et al. Effect of erythromycin before endoscopy in patients presenting with variceal bleeding: a prospective, randomized, double-blind, placebo-controlled trial. Gastrointest Endosc 2011; 73:245.</a></li><li><a class="nounderline abstract_t">Cerqueira RM, Andrade L, Correia MR, et al. Risk factors for in-hospital mortality in cirrhotic patients with oesophageal variceal bleeding. Eur J Gastroenterol Hepatol 2012; 24:551.</a></li><li><a class="nounderline abstract_t">Krige JE, Kotze UK, Distiller G, et al. Predictive factors for rebleeding and death in alcoholic cirrhotic patients with acute variceal bleeding: a multivariate analysis. World J Surg 2009; 33:2127.</a></li><li><a class="nounderline abstract_t">Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368:11.</a></li><li><a class="nounderline abstract_t">Hou MC, Lin HC, Liu TT, et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology 2004; 39:746.</a></li><li><a class="nounderline abstract_t">Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review. Aliment Pharmacol Ther 2011; 34:509.</a></li><li><a class="nounderline abstract_t">Hwang JH, Shergill AK, Acosta RD, et al. The role of endoscopy in the management of variceal hemorrhage. Gastrointest Endosc 2014; 80:221.</a></li><li><a class="nounderline abstract_t">Tandon P, Abraldes JG, Keough A, et al. Risk of Bacterial Infection in Patients With Cirrhosis and Acute Variceal Hemorrhage, Based on Child-Pugh Class, and Effects of Antibiotics. Clin Gastroenterol Hepatol 2015; 13:1189.</a></li><li><a class="nounderline abstract_t">Fernández J, Ruiz del Arbol L, Gómez C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006; 131:1049.</a></li><li><a class="nounderline abstract_t">Mallet M, Rudler M, Thabut D. Variceal bleeding in cirrhotic patients. Gastroenterol Rep (Oxf) 2017; 5:185.</a></li><li><a class="nounderline abstract_t">Fernández J, Navasa M, Gómez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35:140.</a></li><li><a class="nounderline abstract_t">Nardelli S, Gioia S, Ridola L, et al. Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis. Hepatology 2019; 70:640.</a></li><li><a class="nounderline abstract_t">Hung TH, Lee HF, Tseng CW, et al. Effect of proton pump inhibitors in hospitalization on mortality of patients with hepatic encephalopathy and cirrhosis but no active gastrointestinal bleeding. Clin Res Hepatol Gastroenterol 2018; 42:353.</a></li><li><a class="nounderline abstract_t">Knochel JP. Hypophosphatemia in the alcoholic. Arch Intern Med 1980; 140:613.</a></li><li><a class="nounderline abstract_t">Chen PH, Chen WC, Hou MC, et al. Delayed endoscopy increases re-bleeding and mortality in patients with hematemesis and active esophageal variceal bleeding: a cohort study. J Hepatol 2012; 57:1207.</a></li><li><a class="nounderline abstract_t">Kaplan DE, Bosch J, Ripoll C, et al. AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology 2023.</a></li><li><a class="nounderline abstract_t">European Association for the Study of the Liver. Electronic address: <span class="__cf_email__" data-cfemail="325753415e5d54545b5157725753415e5d54545b51571c5747">[email protected]</span>, European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol 2019; 70:172.</a></li><li><a class="nounderline abstract_t">Hébuterne X, Vanbiervliet G. Feeding the patients with upper gastrointestinal bleeding. Curr Opin Clin Nutr Metab Care 2011; 14:197.</a></li><li><a class="nounderline abstract_t">Seo YS. Prevention and management of gastroesophageal varices. Clin Mol Hepatol 2018; 24:20.</a></li><li><a class="nounderline abstract_t">Sharma P, Agrawal A, Sharma BC, et al. Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol 2011; 26:996.</a></li></ol></div><div id="topicVersionRevision">Topic 1254 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24172184" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A risk scoring system to predict in-hospital mortality in patients with cirrhosis presenting with upper gastrointestinal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20638742" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25887380" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30947834" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Portal Hypertension and Related Complications: Diagnosis and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12518132" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Endotracheal intubation for airway protection during endoscopy for severe upper GI hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35120736" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Baveno VII - Renewing consensus in portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21333385" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Erythromycin infusion or gastric lavage for upper gastrointestinal bleeding: a multicenter randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21145052" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effect of erythromycin before endoscopy in patients presenting with variceal bleeding: a prospective, randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22356784" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Risk factors for in-hospital mortality in cirrhotic patients with oesophageal variceal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19672651" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Predictive factors for rebleeding and death in alcoholic cirrhotic patients with acute variceal bleeding: a multivariate analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23281973" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Transfusion strategies for acute upper gastrointestinal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999693" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21707680" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25034836" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The role of endoscopy in the management of variceal hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25460564" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Risk of Bacterial Infection in Patients With Cirrhosis and Acute Variceal Hemorrhage, Based on Child-Pugh Class, and Effects of Antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17030175" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28852523" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Variceal bleeding in cirrhotic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11786970" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30289992" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29551615" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effect of proton pump inhibitors in hospitalization on mortality of patients with hepatic encephalopathy and cirrhosis but no active gastrointestinal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7190373" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Hypophosphatemia in the alcoholic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22885718" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Delayed endoscopy increases re-bleeding and mortality in patients with hematemesis and active esophageal variceal bleeding: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37870298" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30144956" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : EASL Clinical Practice Guidelines on nutrition in chronic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21252654" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Feeding the patients with upper gastrointestinal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29249128" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prevention and management of gastroesophageal varices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21129028" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
